We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Therapeutic Goods Act 1989
Approval under section 42DF for use of restricted representations by Alcon Laboratories Australia Pty Ltd
I, Rowena Love, as a delegate of the Secretary to the Department of Health and Aged Care, on receipt of an application from Alcon Laboratories Australia Pty Ltd, have approved under section 42DF of the Therapeutic Goods Act 1989, the use of the restricted representation in paragraph (A), in advertisements for the products identified in paragraph (B), when the statements identified in paragraph (C) are prominently displayed or communicated[1] in such advertisements.
(A)
- Wavelight Plus is a laser eye surgery treatment that can offer vision correction for people with myopia with and without astigmatism.
(B)
- Ophthalmic excimer laser system (ARTG 172400)
- Anterior eye segment analysis system (ARTG 329115)
(C)
- Consult your eye doctor to see if laser vision correction with WaveLight Plus is suitable for you.
- WaveLight Plus is a surgical treatment and any surgical procedure carries risk.
- Individual results may vary.
Dated this 24th day of January 2024
Signed electronically,
Rowena Love
Delegate of the Secretary to the Department of Health and Aged Care
Advertising and Compliance Education and Policy Section
Regulatory Compliance Branch
[1] As defined in the applicable version of the Therapeutic Goods Advertising Code, as amended from time to time.